SML0836

ML297

≥98% (HPLC)

• 同義詞: 1-(3,4-Difluorophenyl)-3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)urea, CID 56642816, VU0456810
• 經驗公式（希爾表示法）: C₁₇H₁₄F₂N₄O
• CAS號碼: 1443246-62-5
• 分子量：: 328.32
• 分類程式碼代碼: 12352200
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 15 mg/mL, clear
• 儲存溫度: −20°C
• SMILES 字串: Fc1c(ccc(c1)NC(=O)Nc2[n](nc(c2)C)c3ccccc3)F
• InChI: 1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10H,1H3,(H2,20,21,24)
• InChI 密鑰: IEKSMUSSYJUQMY-UHFFFAOYSA-N

描述

生化／生理作用

ML297 (VU0456810) is the first potent and selective activator of the GIRK potassium channel. The G protein-coupled inwardly-rectifying potassium channels (GIRKs 1-4) are widely distributed broadly in the central nervous system (GIRKs 1-3) and also found in the heart (GIRK-4). ML297 activates GIRK channels containing a GIRK1 subunit, and does not activate channels without a GIRK1 subunit or the closely related potassium channel Kir2.1 or voltage-gated potassium channels. ML297 has been shown to activate GIRK1/2 with a potency of ~160 nM and also to activate GIRK channels comprising of GIRK1/3 and GIRK1/4 subunit combinations. ML297 was active in two in vivo models of epilepsy, and showed equal or greater efficacy than the anti-seizure medication, sodium valproate.

特點和優勢

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

安全資訊

• 象形圖: GHS09
• 訊號詞: Warning
• 危險聲明: H410
• 防範說明: P273 - P391 - P501
• 危險分類: Aquatic Acute 1 - Aquatic Chronic 1
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable